Research documentation · About
About Legal PT-141
A documentation-grade editorial digest of the PT-141 (bremelanotide) record — what the approval covers, what the trials measured, and where the evidence stands.
What this site is
Legal PT-141 is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and the approved FDA label.
The "legal" in the domain name is editorial framing — a due-diligence position the publisher occupies relative to the literature and the regulatory record, not a claim that the site provides legal advice, dispenses anything, or offers any service. It signals the question this digest answers: what is actually approved, for whom, and where the evidence sits.
How we read the record
PT-141 / bremelanotide is one of the most documentation-shaped compounds we cover: an FDA-approved drug (NDA 210557, June 2019) with a real structured product label, two pivotal Phase 3 RCTs (RECONNECT, n=1267) with named coprimary endpoints, a 52-week open-label extension, and a published debate over effect size. That structure is why this site reads like a specification rather than a landing page.
We hold two things in the same frame on purpose. The trials met their coprimary endpoints (FSFI-desire +0.35, FSDS-DAO item 13 -0.33, both P<.001) [3]; independent re-analyses argue those effects are statistically real but clinically modest [3]. Both are true, and we report both. We also keep the approval scope exact — premenopausal women with HSDD, everything else off-label — and we foreground the honest tolerability record rather than burying it.
Evidence and field reports, kept separate
Every quantitative clinical claim on this site is cited to a study or the FDA label. Separately, and clearly labeled, we summarize commonly-described community field reports — first-hand accounts that circulate in non-clinical discussion. Those are presented as unverified, attributed to no journal, and fenced off from the cited evidence so an anecdote is never mistaken for a trial result. We summarize patterns; we fabricate no quotes and no numbers, and we describe no protocol for anyone to follow.
This is a reading of published science and the approved record. It is not a substitute for a qualified professional, and nothing here is a recommendation to obtain or administer any compound.